Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
Authors:
Open Access
- 14 February 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 55
Abstract
Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO2) are the key enzymes of tryptophan (TRP) metabolism in the kynurenine pathway (KP). Both enzymes function as indicators of immunosuppression and poor survival in cancer patients. Direct or indirect targeting of either of these substances seems thus reasonable to improve therapy options for patients. In this study, glioblastoma multiforme (GBM) as well as head and neck squamous cell carcinomas (HNSCC) were examined because of their different mechanisms of spontaneous and treatment-induced immune escape. Effects on gene expression and protein levels were examined. Accompanying assessment of TRP metabolites from treated GBM cell culture supernatants was conducted. Our results show a heterogeneous and inversely correlated expression profile of TRP-metabolizing genes among GBM and HNSCC cells, with low, but inducible IDO1 expression upon IFNγ treatment. TDO2 expression was higher in GBM cells, while genes encoding kynurenine aminotransferases were mainly confined to HNSCC cells. These data indicate that the KP is active in both entities, with however different enzymes involved in TRP catabolism. Upon treatment with Temozolomide, the standard of care for GBM patients, IDO1 was upregulated. Comparable, although less pronounced effects were seen in HNSCC upon Cetuximab and conventional drugs (i.e., 5-fluorouracil, Gemcitabine). Here, IDO1 and additional genes of the KP (KYAT1, KYAT2, and KMO) were induced. Vice versa, the novel yet experimental cyclin-dependent kinase inhibitor Dinaciclib suppressed KP in both entities. Our comprehensive data imply inhibition of the TRP catabolism by Dinaciclib, while conventional chemotherapeutics tend to activate this pathway. These data point to limitations of conventional therapy and highlight the potential of targeted therapies to interfere with the cells' metabolism more than anticipated.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft
This publication has 54 references indexed in Scilit:
- IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis DevelopmentCancer Discovery, 2012
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenaseProceedings of the National Academy of Sciences, 2012
- Serum Indoleamine 2,3-Dioxygenase Activity Predicts Prognosis of Pulmonary TuberculosisClinical and Vaccine Immunology, 2012
- Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functionsJournal of Neuroimmunology, 2010
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase InhibitorMolecular Cancer Therapeutics, 2010
- Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapyJournal of Neurosurgery, 2009
- Tumor immune escape mediated by indoleamine 2,3-dioxygenaseImmunology Letters, 2007
- In Vivo Uptake and Metabolism of α-[11C]Methyl-l-Tryptophan in Human Brain TumorsJournal of Cerebral Blood Flow & Metabolism, 2006
- Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.Clinical Cancer Research, 2006
- Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neuronsGlia, 2004